An effective approach to optimizing medicinal molecules

16-Aug-2018 - The search for new medicinal molecules with predetermined properties is a rather complex, expensive and time-consuming process, especially in oncology. Modern science allows us to accelerate this search through the use of computer technology and the introduction of automated processes. In the ...

Phenomenex Launches Chiral Screening Service

25-Mar-2010 - Phenomenex Inc. announces a Chiral Screening Service for customers in pharmaceutical and natural products research and development. This free service provides target screening using a library of HPLC and SFC columns including the Phenomenex Lux polysaccharide-based offerings. After resolving ...

Thermo Fisher Scientific Extends Informatics Offering into Venezuela and the Caribbean Signs Agreement with Controval

15-Nov-2007 - Thermo Fisher Scientific Inc. has signed an agreement with Caracas-based Controval, C.A. to operate an authorized sales center for Thermo Scientific informatics solutions in Venezuela and the Caribbean. Under the terms of the partnership, Controval will be providing professional sales services to ...

Early Screening, Innovative Solutions to Underline Importance of ADME/Tox Technologies in Successful Drug Development

Considerable Time, Cost Savings to Accrue from Advanced ADME/Tox Technologies

10-Aug-2005 - Typically, new drug approval is a protracted, expensive and complex process. Approximately 90 per cent of clinical candidates fail during the development stage with the estimated costs due to poor absorption, distribution, metabolism, elimination (ADME) or toxicity properties itself pegged at ...

Non-Invasive Imaging Tools May Help Unravel Mechanisms of Prenatal Drug Damage

Technique may also help assess, improve effectiveness of pain medication following fetal surgery

08-Feb-2005 - Scientists at the U.S. Department of Energy's Brookhaven National Laboratory demonstrate a new way to assess the potentially damaging effects of prenatal drug exposure -- a technique that could also be used to monitor a fetus's response to therapeutic drugs -- using sophisticated, non-invasive ...

Leadership in Drug Discovery

Schrödinger Releases FirstDiscovery 2.0

26-Jun-2002 - Portland, OR - Schrödinger is pleased to announce the release of FirstDiscovery 2.0, which contains breakthrough technology designed to accelerate the drug-discovery process and reduce development costs. Leading pharmaceutical and biopharmaceutical companies, including Aventis, Boehringer- ...

Schrödinger Announces the Release of FirstDiscovery 1.8

12-Nov-2001 - Schrödinger, Inc. is pleased to announce the general availability of version 1.8 of the FirstDiscovery suite, which contains breakthrough technologies designed to accelerate the drug discovery process and reduce overall costs. Leading pharmaceutical and drug discovery companies, including ...

Tolerability Demonstrated by ABX-EGF as Monotherapy in Advanced Cancers

15-May-2001 - Researchers presented preliminary results from a Phase 1 clinical trial of ABX-EGF, the only fully human monoclonal antibody in development against the epidermal growth factor receptor (EGFr), a receptor identified in many solid tumor types. Co-developed by Abgenix, Inc. (Nasdaq: ABGX) and ...

Cognigen Corporation And Bristol-Myers Squibb Team Up To Bring e-Strategies To Drug Development

Partnership will Facilitate Exchange and Review of Data During U.S. Food and Drug Administration (FDA) Application Process

28-Oct-2000 - BUFFALO, NEW YORK (October 24, 2000) -- Cognigen Corporation, a global analytical communication company, today announced an Internet-based collaboration with Bristol-Myers Squibb Company (NYSE: BMY) that is expected to reduce the timeline for drug development. Through a significant ...